Keyword: Protein Sciences
Washington-based CDMO AGC Biologics said it will expand its headquarters and manufacturing capacity.
Amid a particularly severe flu season, FDA chief Scott Gottlieb said the "holy grail" of vaccines—a shot that fights any strain of virus—is years off.
During the two-plus years of Seqirus' existence, the company has worked to hone its portfolio and boost output of next-gen cell culture flu vaccines.
Not long after its acquisition by Sanofi, Protein Sciences is bidding adieu to its former leader.
Here's some other vaccine news of note for the week.
Egg-based production dampened the effects of last year's flu vaccine, a new study says. What's worse, the problem could repeat this year.
Here's other vaccine news of note for this week.
It's summer, when few are thinking about the coming influenza threat. But top vaccine makers are already kicking off their flu shot shipments.
Though not nearly on the scale of Sanofi's runs at Medivation or Actelion, the Protein Sciences buyout promises a boost for its flu vaccines lineup.
The U.S. could run into a vaccine supply predicament if an influenza pandemic hits, since only one drugmaker has a domestic facility with egg-based vaccine production capabilities.